Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation

Nephrology

Volumn 18, Issue 12, 2013, Pages 820-826

  Kim, Myung Gyu ^a,b   Kim, Yoon Jung ^b,c   Kwon, Hyuk Yong ^b,c   Park, Hayne Cho ^b,c   Koo, Tai Yeon ^b   Jeong, Jong Cheol ^b,c   Jeon, Hee Jung ^c   Han, Miyeun ^c   Ahn, Curie ^b,c   Yang, Jaeseok ^b,c  

^a College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

bortezomib; chronic antibody mediated rejection; immunoglobulin; plasmapheresis; rituximab

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; BORTEZOMIB; COTRIMOXAZOLE; CYCLOSPORIN A; IMMUNOGLOBULIN; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS; ALLOANTIBODY; BORONIC ACID DERIVATIVE; HLA ANTIGEN; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY MEDIATED REJECTION; ARTICLE; CHRONIC ANTIBODY MEDIATED REJECTION; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; FEMALE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT PLANNING; BLOOD; CHRONIC DISEASE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; CHRONIC DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMAPHERESIS; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 84888862075     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12157     Document Type: Article

References (22)

1. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 2001; 12: 574-582.
2. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55: 713-723.
3. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am. J. Transplant. 2007; 7: 2124-2132.
4. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J. Am. Soc. Nephrol. 2002; 13: 2371-2380.
5. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am. J. Transplant. 2007; 7: 1743-1752.
6. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am. J. Transplant. 2008; 8: 753-760.
7. Colvin RB,. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J. Am. Soc. Nephrol. 2007; 18: 1046-1056.
8. Farris AB, Gaut J, Wong W, et al. Pathology, serology and clinical characteristics of 68 patients with chronic humoral renal allograft rejection. Mod. Pathol. 2009; 22 (Suppl 1): 302A-303.
9. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am. J. Transplant. 2006; 6: 1841-1847.
10. Smith RN, Colvin RB,. Chronic alloantibody mediated rejection. Semin. Immunol. 2012; 24: 115-121.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999; 130: 461-470.
12. Billing H, Rieger S, Ovens J, et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008; 86: 1214-1221.
13. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A,. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87: 1837-1841.
14. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754-1761.
15. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant. 2009; 9: 201-209.
16. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555-1561.
17. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S,. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. 2006; 6: 346-351.
18. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K,. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010; 89: 1466-1470.
19. Uchida J, Machida Y, Iwai T, et al. Desensitization protocol in highly HLA-sensitized and ABO-incompatible high titer kidney transplantation. Transplant. Proc. 2010; 42: 3998-4002.
20. Ntokou IS, Iniotaki AG, Kontou EN, et al. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: High immunogenicity of HLA class II graft molecules. Transpl. Int. 2011; 24: 1084-1093.
21. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am. J. Transplant. 2010; 10: 89-98.
22. Kumar D, Gourishankar S, Mueller T, et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl. Infect. Dis. 2009; 11: 167-170.